跳至主要内容
临床试验/NCT00266513
NCT00266513终止不适用

Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

National Institute of Allergy and Infectious Diseases (NIAID)1 个研究点 分布在 1 个国家目标入组 119 人开始时间: 2005年12月14日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
119
试验地点
1

研究概览

简要总结

This study investigates gene abnormalities in Primary Immune Deficiency(PID) with a goal of improving the diagnosis and treatment of patients.

The specific disorders include:

  1. X linked hyper IgM Syndrome which is caused by an abnormality in the CD40L gene.
  2. NEMO associated immune deficiency which is caused by an abnormality in a gene called NEMO.
  3. Common variable immunodeficiency (CVID) which has an unknown genetic basis.
  4. Other disorders of immunoglobulin production.

This study will:

  1. Better characterize the clinical features of CD40 L deficiency and NEMO associated immune deficiency and other related primary immune deficiency syndromes.
  2. Determine the frequency of CD40 L and Nemo abnormalities.
  3. Determine whether particular abnormalities in these genes are associated with more of less severe illness or with specific symptoms.
  4. Explore the basic mechanism by which these altered genes cause immune dysfunction.
  5. Identify other genes causing low immune globulin levels and related primary immune deficient states.

详细描述

This protocol is designed to study the genetics and pathophysiology of Hyper-IgM syndrome, NEMO associated immune deficiency, patients with related primary immune deficiency disorders, and the blood relatives of immunodeficient patients. Patients will undergo evaluations that include history/physical, blood sampling, genetic testing, and possible tissue sampling. Among the aims of this protocol are to better understand genetic factors that lead to defects in host defense, and to use modern and evolving methods in molecular and cellular biology to elucidate the pathogenesis of these diseases. A better understanding of primary immunodeficiency could allow for the rational development of novel therapies for such diseases and to benefit future patients, but it might not benefit current patients directly. Routine follow-up may occur every six months - with evaluation and blood sampling. Under some circumstances, we may provide treatment that relates to the immune deficiency. These treatments will follow standard medical practice.

研究设计

研究类型
Observational

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

研究点 (1)

Loading locations...

相似试验